ASX Growth Companies With At Least 10% Insider Ownership

In This Article:

Amidst fluctuations in commodity prices and a slight anticipated dip in the ASX200, investors continue to navigate the complexities of the Australian market. In such an environment, growth companies with high insider ownership can offer a unique appeal, potentially aligning management interests closely with shareholder outcomes in these turbulent times.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Hartshead Resources (ASX:HHR)

13.9%

86.3%

Cettire (ASX:CTT)

28.7%

29.9%

Gratifii (ASX:GTI)

15.6%

112.4%

Acrux (ASX:ACR)

14.6%

115.3%

Alpha HPA (ASX:A4N)

26.3%

95.9%

Botanix Pharmaceuticals (ASX:BOT)

11.4%

120.9%

Hillgrove Resources (ASX:HGO)

10.4%

45.4%

Change Financial (ASX:CCA)

26.6%

85.4%

Plenti Group (ASX:PLT)

12.8%

106.4%

Liontown Resources (ASX:LTR)

16.4%

63.9%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Bell Financial Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Bell Financial Group Limited, operating in Australia, offers a range of services including broking, online broking, corporate finance, and financial advisory to private, institutional, and corporate clients with a market capitalization of approximately A$0.42 billion.

Operations: The company generates revenue through four primary segments: retail broking (A$103.58 million), institutional broking (A$50.36 million), financial products and services (A$48.10 million), and technology and platform services (A$26.20 million).

Insider Ownership: 10.7%

Bell Financial Group is poised for notable growth, with earnings expected to increase by 26.95% annually over the next three years, outpacing the Australian market's forecast of 13.9%. Despite a low return on equity forecast at 16.3%, the company trades at a significant discount of 25.3% below estimated fair value, suggesting potential undervaluation. Revenue growth projections stand at 5.6% per year, slightly above the market average of 5.3%. However, its dividend sustainability is questionable as it is not well covered by earnings or cash flows.

ASX:BFG Earnings and Revenue Growth as at Jun 2024
ASX:BFG Earnings and Revenue Growth as at Jun 2024

Botanix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★★

Overview: Botanix Pharmaceuticals Limited, based in Australia, focuses on the research and development of dermatology and antimicrobial products with a market capitalization of approximately A$448.91 million.